---
title: "BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299440030.md"
description: "Improved financial position through the successful closing of a larger-than-planned $168.3 million initial public offering."
datetime: "2026-09-18T11:02:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299440030.md)
  - [en](https://longbridge.com/en/news/299440030.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299440030.md)
generator: "portal-rs"
---

# BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Improved financial position through the successful closing of a larger-than-planned $168.3 million initial public offering.

### Related Stocks

- [BLSM.US](https://longbridge.com/en/quote/BLSM.US.md)

## Related News & Research

- [BLSM: Q2 2026 net loss widened to $23.8M as R&D ramped up; IPO raised $151.7M for future operations](https://longbridge.com/en/news/299441702.md)
- [BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned](https://longbridge.com/en/news/299043586.md)
- [Baidu Steps Up Hong Kong Share Buybacks Under August 2026 Mandate](https://longbridge.com/en/news/299441763.md)
- [BlossomHill Therapeutics (NASDAQ:BLSM) Now Covered by Analysts at JPMorgan Chase & Co.](https://longbridge.com/en/news/297657599.md)
- [McDonald's Stock (MCD) Looks Tastier as It Gets Set For Another Value Meals Revamp](https://longbridge.com/en/news/299444824.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**